Harvard Bioscience Q4 revenue $24.6M, FY 2024 net loss widens to $12.4M

HARVARD BIOSCIENCE INC

Q4 2024 revenue $24.6M, down 12.8% from $28.2M in Q4 2023.
Full-year 2024 revenue $94.1M vs $112.3M; net loss $(12.4)M vs $(3.4)M.
Adjusted EBITDA fell to $7.2M from $14.6M; operating cash flow dropped to $1.4M from $14.0M.
CEO cites challenging market; highlights SoHo telemetry and MeshMEA organoid systems as growth drivers.
Q4 net income was $18K vs loss of $(1.8)M in Q4 2023 (slight improvement in quarter).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.